Search | Page 8 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies

    ... MDS/CMML (defined as ≥ 10% peripheral blood or marrow blasts and/or IPSS score ≥ 1.5) and relapsed or refractory to ...

    Clinical Trial last updated 06/06/2016 - 10:47am.

  2. Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies (AB-CliniMACs)

    ... Disease status: remission or <10% bone marrow blasts Myelodysplasia Acute lymphoblastic leukemia Disease status: ...

    Clinical Trial last updated 06/03/2016 - 2:45pm.

  3. Phase I, Dose Escalation Study of Decitabine

    ... (CR) following allo-HSCT ( bone marrow leukemic blasts less than 5% by morphology ), with high risk features ...

    Clinical Trial last updated 06/06/2016 - 9:44am.

  4. Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

    ... syndrome (MDS) (defined as having >/= 10% blasts in the bone marrow ) or patients with Chronic Myelomonocytic Leukemia (CMML) (having >/= 10% blasts in the bone marrow) may also be eligible after discussion with Principal ...

    Clinical Trial last updated 05/23/2016 - 3:37pm.

  5. FAQs

    ... cells in your bone marrow being young white blood cells ( blasts ). About 30 out of 100 people with MDS will develop AML. Certain ... you have 3. Percentage of young white blood cells ( blasts ) in your bone marrow. 4. The number of cytogenetic changes you ...

    Topic section last updated 03/02/2016 - 11:42am.

  6. UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep

    ... Must be in remission by morphology (<5% blasts ). Note cytogenetic relapse or persistent disease without morphologic relapse is acceptable. Also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are ...

    Clinical Trial last updated 04/29/2016 - 10:06am.

  7. Study of Clinical Efficacy and Safety of Tosedostat in MDS (IST-CTI-MDS)

    ... adult patients with pathologically confirmed MDS (< 20% blasts in bone marrow , peripheral blood, or both) by World Health ...

    Clinical Trial last updated 05/03/2016 - 9:46am.

  8. Allo HSCT Using RIC for Hematological Diseases

    ... be in CR as defined by hematological recovery, AND <5% blasts by light microscopy within the bone marrow with a ... <21 years, however, are eligible with (M2 marrow) with < 25% blasts in marrow after having failed one or more cycles of chemotherapy ...

    Clinical Trial last updated 05/02/2016 - 9:29am.

  9. Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS (AML)

    ... or morphologic complete remission or MDS - Marrow blasts must be > 5% and disease failed at least 1 prior hypomethylating ...

    Clinical Trial last updated 05/02/2016 - 11:06am.

  10. Specialized technique effective in identifying chromosomal abnormalities, improving prognosis for MDS

    ... based solely on the percentage of bone marrow blasts , cytogenetics (branch of genetics which studies the ...

    Research Review last updated 05/02/2016 - 9:31am.